1
|
A Narrative Review of 99mTc-Aprotinin in the Diagnosis of Cardiac Amyloidosis and a New Life for an Unfairly Abandoned Drug. Biomedicines 2022; 10:biomedicines10061377. [PMID: 35740399 PMCID: PMC9219762 DOI: 10.3390/biomedicines10061377] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2022] [Revised: 05/26/2022] [Accepted: 06/07/2022] [Indexed: 11/17/2022] Open
Abstract
Several studies investigated the use of 99mTc-labelled Aprotinin as an amyloid seeker some years ago. In vitro tests showed high binding affinity for several types of amyloid fibrils accompanied by an excellent specificity. Initial human studies demonstrated good accuracy in detecting cardiac involvement. Scintigraphy results were confirmed in a group of 28 endomyocardial biopsies. Unfortunately, clinical studies were halted because of a temporary suspension of the vector protein (Trasylol) and public health concerns over prion contamination of the bovine origin compound. To obviate these limitations, efforts have been made to label a recombinant Aprotinin with 99mTc, which exhibits the same affinity for h-insulin fibrils. With the aim of developing a PET tracer, the same recombinant protein was labeled with Gallium. The introduction of a bifunctional chelator did not affect fibril affinity. Finally, a synthetic peptidic fragment, the cyclic 30-51 SS, was synthetized. After direct technetium labeling, an impressive increase in affinity was demonstrated. This peptide appears to be a potential candidate for Gallium labeling through a bifunctional chelator for PET imaging.
Collapse
|
2
|
In Vivo Microbial Targeting of 99mTc-Labeled Human β-Defensin-3 in a Rat Model of Infection. Clin Nucl Med 2019; 44:e602-e606. [PMID: 31306193 DOI: 10.1097/rlu.0000000000002713] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
OBJECTIVE Differentiation of infection from aseptic inflammation represents a major clinical issue. None of the commercially available compounds (labeled granulocytes, antigranulocyte antibodies, Ga-citrate, labeled immunoglobulin G, F-FDG) is capable of this differentiation, producing a nonnegligible false-positive rate. Recently, our group reported on a reliable labeling procedure of the antimicrobial peptide human β-defensin 3 (HBD-3) with Tc. The aim of this study was to evaluate in vivo Tc-HBD-3 uptake in a rat model of infection. METHODS Recombinant HBD-3 was radiolabeled with Tc. Radiolabeling yield and specific activity of the compound were calculated. Chromatographic behavior and biological activity of Tc-HBD-3 were also assessed. An experimental model involving Staphylococcus aureus-induced infection and carrageenan-induced aseptic inflammation was performed in 5 Wistar rats. Serial planar scintigraphic acquisitions were performed from 15 to 180 minutes after Tc-HBD-3 intravenous administration. Radiotracer uptake was evaluated qualitatively and semiquantitatively as a target-to-nontarget ratio. RESULTS Radiolabeling yield of Tc-HBD-3 was 70% with a specific activity of 6 to 8 MBq/μg. A significant and progressive Tc-HBD-3 uptake was observed in the site of S. aureus-induced infection, with a maximum average target-to-nontarget ratio of 5.7-fold higher in the infection site compared with an inflammation site observed at 140 minutes. CONCLUSIONS In vivo imaging with Tc-HBD-3 in a rat model of S. aureus-induced infection demonstrated favorable uptake in the infection site compared with sterile inflammation and background. These promising results, together with previous ex vivo uptake and toxicity assessment, suggest the potential of Tc-HBD-3 as a novel agent for specific infection imaging.
Collapse
|
3
|
Karachaliou CE, Triantis C, Liolios C, Palamaris L, Zikos C, Tsitsilonis OE, Kalbacher H, Voelter W, Loudos G, Papadopoulos M, Pirmettis I, Livaniou E. In vivo biodistribution and imaging studies with a 99mTc-radiolabeled derivative of the C-terminus of prothymosin alpha in mice bearing experimentally-induced inflammation. Eur J Pharm Biopharm 2017; 113:188-197. [PMID: 28087377 DOI: 10.1016/j.ejpb.2016.12.028] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2016] [Revised: 11/15/2016] [Accepted: 12/14/2016] [Indexed: 10/20/2022]
Abstract
Prothymosin alpha (ProTα) is a highly conserved mammalian polypeptide (109 amino acids in man) exerting in vitro and in vivo immunoenhancing activities. Recently, our team has developed a 99mTc-radiolabeled derivative of the C-terminal bioactive decapeptide of ProTα ([99mTc]C1) and employed it in in vitro studies, the results of which support the existence of binding sites on human neutrophils that recognize [99mTc]C1, intact ProTα as well as the C-terminal decapeptide of ProTα and presumably involve Toll-like receptor 4. In the present work, [99mTc]C1 was administered to Swiss albino mice with experimentally-induced inflammation for in vivo biodistribution and imaging studies, in parallel with a suitable negative control, which differs from [99mTc]C1 only in bearing a scrambled version of the ProTα decapeptide. The biodistribution data obtained with [99mTc]C1 demonstrated fast clearance of radioactivity from blood, heart, lungs, normal muscle, and predominantly urinary excretion. Most importantly, slow clearance of radioactivity from the inflammation focus was observed, resulting in a high ratio of inflamed/normal muscle tissue (9.15 at 30min post injection, which remained practically stable up to 2h). The inflammation-targeting capacity of [99mTc]C1 was confirmed by imaging studies and might be attributed to neutrophils, which are recruited at the inflamed areas and bear binding sites for [99mTc]C1. In this respect, apart from being a valuable tool for further studies on ProTα in in vitro and in vivo systems, [99mTc]C1 merits further evaluation as a radiopharmaceutical for specific imaging of inflammation foci.
Collapse
Affiliation(s)
- Chrysoula-Evangelia Karachaliou
- Institute of Nuclear and Radiological Sciences and Technology, Energy and Safety (INRASTES), National Center for Scientific Research "Demokritos" (NCSR "Demokritos"), Athens 15310, Greece
| | - Charalampos Triantis
- Institute of Nuclear and Radiological Sciences and Technology, Energy and Safety (INRASTES), National Center for Scientific Research "Demokritos" (NCSR "Demokritos"), Athens 15310, Greece
| | - Christos Liolios
- Institute of Nuclear and Radiological Sciences and Technology, Energy and Safety (INRASTES), National Center for Scientific Research "Demokritos" (NCSR "Demokritos"), Athens 15310, Greece
| | - Lazaros Palamaris
- Department of Medical Instruments Technology, Technological Educational Institute, Athens 12243, Greece
| | - Christos Zikos
- Institute of Nuclear and Radiological Sciences and Technology, Energy and Safety (INRASTES), National Center for Scientific Research "Demokritos" (NCSR "Demokritos"), Athens 15310, Greece
| | - Ourania E Tsitsilonis
- Division of Animal and Human Physiology, Department of Biology, University of Athens, Athens 15784, Greece
| | - Hubert Kalbacher
- Interfaculty Institute of Biochemistry, University of Tuebingen, Tuebingen 72076, Germany
| | - Wolfgang Voelter
- Interfaculty Institute of Biochemistry, University of Tuebingen, Tuebingen 72076, Germany
| | - George Loudos
- Department of Medical Instruments Technology, Technological Educational Institute, Athens 12243, Greece
| | - Minas Papadopoulos
- Institute of Nuclear and Radiological Sciences and Technology, Energy and Safety (INRASTES), National Center for Scientific Research "Demokritos" (NCSR "Demokritos"), Athens 15310, Greece
| | - Ioannis Pirmettis
- Institute of Nuclear and Radiological Sciences and Technology, Energy and Safety (INRASTES), National Center for Scientific Research "Demokritos" (NCSR "Demokritos"), Athens 15310, Greece
| | - Evangelia Livaniou
- Institute of Nuclear and Radiological Sciences and Technology, Energy and Safety (INRASTES), National Center for Scientific Research "Demokritos" (NCSR "Demokritos"), Athens 15310, Greece.
| |
Collapse
|
4
|
Azzopardi EA, Conlan RS, Whitaker IS. Polymer therapeutics in surgery: the next frontier. ACTA ACUST UNITED AC 2016; 1:19-29. [PMID: 27588210 PMCID: PMC4985703 DOI: 10.1002/jin2.6] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2015] [Revised: 11/18/2015] [Accepted: 11/20/2015] [Indexed: 01/13/2023]
Abstract
Polymer therapeutics is a successful branch of nanomedicine, which is now established in several facets of everyday practice. However, to our knowledge, no literature regarding the application of the underpinning principles, general safety, and potential of this versatile class to the perioperative patient has been published. This study provides an overview of polymer therapeutics applied to clinical surgery, including the evolution of this demand‐oriented scientific field, cutting‐edge concepts, its implications, and limitations, illustrated by products already in clinical use and promising ones in development. In particular, the effect of design of polymer therapeutics on biophysical and biochemical properties, the potential for targeted delivery, smart release, and safety are addressed. Emphasis is made on principles, giving examples in salient areas of demand in current surgical practice. Exposure of the practising surgeon to this versatile class is crucial to evaluate and maximise the benefits that this established field presents and to attract a new generation of clinician–scientists with the necessary knowledge mix to drive highly successful innovation.
Collapse
Affiliation(s)
- Ernest A Azzopardi
- Reconstructive Surgery and Regenerative Medicine Research Unit, Institute for Life Science Swansea University Medical School, Swansea University Singleton Park Campus SwanseaSA2 8PP UK; The Welsh Centre for Burns and Plastic Surgery Moriston Hospital Swansea Swansea SA6 6NL UK; Institute for Life Science and Centre for NanoHealth Swansea University Medical School, Swansea University Singleton Park Campus Swansea SA2 8PP UK
| | - R Steven Conlan
- Institute for Life Science and Centre for NanoHealth Swansea University Medical School, Swansea University Singleton Park Campus Swansea SA2 8PP UK
| | - Iain S Whitaker
- Reconstructive Surgery and Regenerative Medicine Research Unit, Institute for Life Science Swansea University Medical School, Swansea University Singleton Park Campus SwanseaSA2 8PP UK; The Welsh Centre for Burns and Plastic Surgery Moriston Hospital Swansea Swansea SA6 6NL UK; Institute for Life Science and Centre for NanoHealth Swansea University Medical School, Swansea University Singleton Park Campus Swansea SA2 8PP UK
| |
Collapse
|
5
|
Kaschwich M, Lützen U, Zhao Y, Tjiong A, Marx M, Haenisch S, Wiedow O, Preuss S, Culman J, Zuhayra M. Biodistribution and pharmacokinetics of the (99m)Tc labeled human elastase inhibitor, elafin, in rats. Drug Metab Pharmacokinet 2016; 31:146-55. [PMID: 26948953 DOI: 10.1016/j.dmpk.2016.01.004] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2015] [Revised: 01/25/2016] [Accepted: 01/27/2016] [Indexed: 11/27/2022]
Abstract
Elafin is a potent reversible inhibitor of the pro-inflammatory proteases leukocyte elastase and protease 3. It is currently in clinical development for the use in postoperative inflammatory diseases. We investigated the pharmacokinetics of (99m)Tc-labeled elafin ((99m)Tc-Elafin) in blood and individual organs in rat after bolus intravenous injection using the single photon emission tomography (SPECT). (99m)Tc-Elafin predominantly accumulated in the kidney reaching a maximum of 8.5% ± 0.1% of the injected dose per gram (ID/g) at 5 min post injection (p.i) and decreased only slowly during 24 h. In contrast, the initially high radio activity recorded in the other organs rapidly decreased parallel to the radioactivity detected in blood. The blood kinetics fits to a two compartment kinetics model. The radio activity in the dissected kidney was 4.98 ± 1.24%ID/g 24 h p.i, while in other organs, including the brain, no accumulation of (99m)Tc-Elafin was detected. At this time point 30% of the detected radioactivity in the kidney was identified to be not metabolized (99m)Tc-Elafin. In conclusion, the blood and organ-specific kinetic data provide a basis for planning of adequate dosing regimens and the high accumulation of intact elafin in the kidney favors clinical developments targeting inflammatory kidney diseases, such as chronic allograft nephropathy after kidney transplantation.
Collapse
Affiliation(s)
- Mark Kaschwich
- Department of Cardiovascular Surgery, University Hospital of Schleswig-Holstein (UK-SH), Campus Kiel, Arnold-Heller-Strasse 3, D-24105 Kiel, Germany
| | - Ulf Lützen
- Department of Nuclear Medicine, Molecular Imaging, Diagnostics and Therapy, University Hospital of Schleswig-Holstein (UK-SH), Campus Kiel, Karl Lennert Cancer Center North, Feldstrasse 21, D-24105, Germany
| | - Yi Zhao
- Department of Nuclear Medicine, Molecular Imaging, Diagnostics and Therapy, University Hospital of Schleswig-Holstein (UK-SH), Campus Kiel, Karl Lennert Cancer Center North, Feldstrasse 21, D-24105, Germany
| | - Angelina Tjiong
- Department of Nuclear Medicine, Molecular Imaging, Diagnostics and Therapy, University Hospital of Schleswig-Holstein (UK-SH), Campus Kiel, Karl Lennert Cancer Center North, Feldstrasse 21, D-24105, Germany
| | - Marlies Marx
- Department of Nuclear Medicine, Molecular Imaging, Diagnostics and Therapy, University Hospital of Schleswig-Holstein (UK-SH), Campus Kiel, Karl Lennert Cancer Center North, Feldstrasse 21, D-24105, Germany
| | - Sierk Haenisch
- Institute of Experimental and Clinical Pharmacology, University Hospital of Schleswig-Holstein (UK-SH), Campus Kiel, Arnold-Heller-Strasse 3, D-24105 Kiel, Germany
| | - Oliver Wiedow
- Department of Dermatology, Venereology and Allergology, University Hospital of Schleswig-Holstein (UK-SH), Campus Kiel, Schittenhelmstrasse 7, D-24105 Kiel, Germany
| | - Stefanie Preuss
- Department of General Pediatrics, University Hospital of Schleswig-Holstein (UK-SH), Campus Kiel, Arnold-Heller-Strasse 9, D-24105 Kiel, Germany
| | - Juraj Culman
- Institute of Experimental and Clinical Pharmacology, University Hospital of Schleswig-Holstein (UK-SH), Campus Kiel, Arnold-Heller-Strasse 3, D-24105 Kiel, Germany
| | - Maaz Zuhayra
- Department of Nuclear Medicine, Molecular Imaging, Diagnostics and Therapy, University Hospital of Schleswig-Holstein (UK-SH), Campus Kiel, Karl Lennert Cancer Center North, Feldstrasse 21, D-24105, Germany.
| |
Collapse
|
6
|
Polyák A, Hajdu I, Bodnár M, Trencsényi G, Pöstényi Z, Haász V, Jánoki G, Jánoki GA, Balogh L, Borbély J. 99mTc-labelled nanosystem as tumour imaging agent for SPECT and SPECT/CT modalities. Int J Pharm 2013; 449:10-7. [DOI: 10.1016/j.ijpharm.2013.03.049] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2012] [Revised: 03/24/2013] [Accepted: 03/26/2013] [Indexed: 01/29/2023]
|
7
|
Benaki D, Zikos C, Karachaliou CE, Tsitsilonis O, Leondiadis L, Kalbacher H, Voelter W, Papadopoulos M, Pirmettis I, Pelecanou M, Livaniou E. Complexes of an Alpha Thymosin Derivative with185/187Re and99mTc: Structural Analysis and Initial Biological Evaluation. Chem Biol Drug Des 2012; 80:545-53. [DOI: 10.1111/j.1747-0285.2012.01425.x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
|
8
|
Liberatore M, Pala A, Scaccianoce S, Anagnostou C, Di Tondo U, Calandri E, D'Elia P, Gross MD, Rubello D. Microbial Targeting of 99mTc-Labeled Recombinant Human β-Defensin-3 in an Animal Model of Infection: A Feasibility Pilot Study. J Nucl Med 2009; 50:823-6. [DOI: 10.2967/jnumed.108.055533] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
9
|
Klimentzou P, Beck A, Varvarigou A, Tsitsilonis O, Voelter W, Pirmettis I, Papadopoulos M, Livaniou E, Zikos C. Solid-phase Synthesis of a Peptide Derivative of Thymosin alpha1 and Initial Studies on its99mTc-Radiolabelling. Chem Biol Drug Des 2007; 70:40-6. [PMID: 17630993 DOI: 10.1111/j.1747-0285.2007.00529.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
A derivative (1) of the immunopotentiating 28-peptide thymosin alpha1 has been especially designed, so that it can be (99m)Tc-radiolabelled, and synthesized following the Fmoc solid-phase peptide synthesis approach. Derivative 1 contains the N-terminal fragment Talpha1[1-14] as a bioactive segment, at the C-terminus of which a (99m)Tc-chelating moiety consisting of N(alpha),N(alpha)-dimethylglycine, serine and cysteine is linked through the N(epsilon)-amino group of a 'bifunctional' lysine residue; the latter is indirectly anchored on the solid-phase peptide synthesis resin through 6-aminocaproic acid (dmGSCK{N(epsilon)-Talpha1[1-14]}Aca). Synthetic derivative 1 was obtained at high overall yield (approximately 35%) and purity (>95%) and shown to be efficiently radiolabelled with (99m)Tc, thus resulting in the first, to our knowledge, so far reported (99m)Tc-radiolabelled derivative of thymosin alpha1, which may be eventually used as a specific molecular tool for the in vitro/in vivo study of the mode of action of the parent bioactive peptide.
Collapse
Affiliation(s)
- Persefoni Klimentzou
- National Centre for Scientific Research 'Demokritos', Aghia Paraskevi Attikis, Athens 15310, Greece
| | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Smyth DR, Tsopelas C. An improved 99mTc-aprotinin kit formulation: quality control analysis of radiotracer stability and cold kit shelf life. Nucl Med Biol 2005; 32:885-9. [PMID: 16253814 DOI: 10.1016/j.nucmedbio.2005.06.006] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2005] [Revised: 06/08/2005] [Accepted: 06/09/2005] [Indexed: 11/28/2022]
Abstract
(99m)Tc-aprotinin scintigraphy has been demonstrated to be a useful noninvasive imaging technique for amyloid deposits located in extraabdominal regions of patients. The aim of this study was to develop an improved aprotinin cold kit formulation, to validate the kit for long-term stability, as well as to assess the radiotracer stability by novel quality control methods. The aprotinin cold kit formulation of Trasylol, pyrophosphate (PYP)-chelated stannous reductant and an alkaline buffer, was dispensed into nitrogen-filled vials and aliquots frozen at -20 degrees C. After 0, 1, 2, 3 and 6 months of storage, three samples were reconstituted with 750-850 MBq of (99m)Tc-pertechnetate, followed by quality control analyses by paper chromatography methods at 25, 85 and 265 min postreconstitution (pr). Cation-exchange cartridge quality control methods were also investigated. The cold kits proved to be stable to long-term storage for up to 6 months, and the radiotracer was stable for at least 4 h pr. (99m)Tc-aprotinin was formed at greater than 95% efficiency at all time points tested with (99m)TcO2 present as the major impurity (1-4%) and (99m)Tc-pertechnetate and (99m)Tc-PYP present in trace amounts. An alternative, rapid, safe and reliable method was found in Oasis MCX-BSA-treated cartridges using saline as the eluting solution to assay for (99m)Tc-aprotinin.
Collapse
Affiliation(s)
- Douglas R Smyth
- Department of Nuclear Medicine, Royal Adelaide Hospital, North Terrace, Adelaide SA 5000, Australia.
| | | |
Collapse
|